Abstract
Aim:
We have shown that a combination of ligustrazine and berberine produces more effective inhibition on platelet activation and inflammatory reactions in rat acute myocardial infarction compared with either agent alone. In this study we evaluated the beneficial effects of a combination of ligustrazine and berberine in a rat model of coronary microembolization (CME).
Methods:
SD rats were treated with ligustrazine, berberine, ligustrazine+berberine, or clopidogrel for 2 weeks. When the treatment completed, CME was induced by injection of sodium laurate into the left ventricular, while obstructing the ascending aorta. All rats were intubated for hemodynamic measurements. Blood samples were collected for biochemical analyses, flow cytometry, and ELISAs. Heart tissues were isolated for histopathology and subsequent protein analyses.
Results:
Pretreatment with the combination of ligustrazine (27 mg·kg−1·d−1) and berberine (90 mg·kg−1·d−1) significantly improved cardiac function, and decreased myocardial necrosis, inflammatory cell infiltration, microthrombosis and serum CK-MB levels in CME rats. In addition, this combination significantly decreased plasma ET-1 levels and von Willebrand factor, inhibited ADP-induced platelet activation, and reduced TNFα, IL-1β, ICAM-1 and RANTES levels in serum and heart tissues. The protective effects of this combination were more prominent than those of ligustrazine or berberine alone, but comparable to those of a positive control clopidogrel (6.75 mg·kg−1·d−1).
Conclusion:
The combination of ligustrazine and berberine significantly improved cardiac function in rat CME model via a mechanism involving antiplatelet and anti-inflammatory effects.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Erbel R, Heusch G . Coronary microembolization. J Am Coll Cardiol 2000; 36: 22–4.
Camici PG, Crea F . Coronary microvascular dysfunction. N Engl J Med 2007; 356: 830–40.
Gulati M, Cooper-DeHoff RM, McClure C, Johnson BD, Shaw LJ, Handberg EM, et al. Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women's Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project. Arch Intern Med 2009; 169: 843–50.
Davì G, Patrono C . Platelet activation and atherothrombosis. New Engl J Med 2007; 357: 2482–94.
Wang H, Zhong WJ, Huang MW, Wu XY Chen H . Efficacy of dual antiplatelet therapy combined with Naoxintong capsules following coronary microembolization induced by homologous microthrombi in rats. Chin J Integr Med 2011; 17: 917–24.
Liu SY, Sylvester DM . Antiplatelet activity of tetramethylpyrazine. Thromb Res 1994; 75: 51–62.
Sheu JR, Kan YC, Hung WC, Ko WC, Yen MH . Mechanisms involved in the antiplatelet activity of tetramethylpyrazine in human platelets. Thromb Res 1997; 88: 259–70.
Li Y, Song P, Zhu Q, Yin QY, Ji JW, Li W, et al. Liguzinediol improved the heart function and inhibited myocardial cell apoptosis in rats with heart failure. Acta Pharmacol Sin 2014; 35: 1257–64.
Ji XX, Song XL, Qian W, Yu XL, Zhu JY . Effects and mechanism of action of ligustrazine on isoprenaline-induced cardiomyocyte hypertrophy. Cell Biochem Biophys 2014; 70: 1513–8.
Kong WJ, Wei J, Abidi P, Lin MH, Inaba S, Li C, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 2004; 10: 1344–51.
Huang ZQ, Han ZH, Ye BZ, Dai ZY, Shan PR, Lu ZQ, et al. Berberine alleviates cardiac ischemia/reperfusion injury by inhibiting excessive autophagy in cardiomyocytes. Eur J Pharmacol 2015; 762: 1–10.
Yu LM, Li FJ, Zhao GL, Yang Y, Jin ZX, Zhai MG, et al. Protective effect of berberine against myocardial ischemia reperfusion injury: role of Notch1/Hes1-PTEN/Akt signaling. Apoptosis 2015; 20: 796–810.
Chen KK, Li GH, Geng FH, Zhang Z, Li JN, Yang M, et al. Berberine reduces ischemia/reperfusion-induced myocardial apoptosis via activating AMPK and PI3K-Akt signaling in diabetic rats. Apoptosis 2014; 19: 946–57.
Zhang YJ, Yang SH, Li MH, Iqbal J, Bouranta CV, Mi QY, et al. Berberine attenuates adverse left ventricular remodeling and cardiac dysfunction after acute myocardial infarction in rats: role of autophagy. Clin Exp Pharmacol Physiol 2014; 41: 995–1002.
Ma XJ, Guo CY, Yin HJ, Liu Y, Shi DZ . Effect of activating blood circulation or activating blood circulation and detoxification on platelet activation, inflammation, and coagulation status in acute myocardial infarction rats. Chin J Integr Tradit West Med 2014; 34: 1329–34.
Li SM, Zhong SS, Zeng K, Luo YK, Zhang FL, Sun XD, et al. Blockade of NF-κB by pyrrolidine dithiocarbamate attenuates myocardial inflammatory response and ventricular dysfunction following coronary microembolization induced by homologous microthrombi in rats. Basic Res Cardiol 2010; 105: 139–50.
Bai YP, Hu LQ, Wu J, Gu Y, Li L, Gao B, et al. Effects of intravenous diltiazem in a rat model of experimental coronary thrombotic microembolism. Exp Ther Med 2013; 6: 873–82.
Shen CX, Liang C, Chen LL, Qian JY, Wang KQ, Chen HZ, et al. The establishment of a new model of rat coronary microthrombosis by coronary sodium laurate injection. Chin J Arterioscl 2005; 13: 447–50.
Toshima Y, Satoh S, Ikegaki I, Asano T . A new model of cerebral microthrombosis in rats and the neuroprotective effect of a Rho-kinase inhibitor. Stroke 2000; 31: 2245–50.
Schumacher WA, Bostwick JS, Ogletree ML, Stewart AB, Steinbacher TE, Hua J, et al. Biomarker optimization to track the antithrombotic and hemostatic effects of clopidogrel in rats. J Pharmacol Exp Ther 2007; 322: 369–77.
Duran JR 3rd, Taffet G . Coronary microvascular dysfunction. N Engl J Med 2007; 356: 2324–5.
Molero L, López-Farré A, Mateos-Cáceres PJ, Fernández-Sánchez R, Maestro ML, Silva J, et al. Effect of clopidogrel on the expression of inflammatory markers in rabbit ischemic coronary artery. Br J Pharmacol 2005; 146: 419–24.
Wong KSL, Chen C, Fu J, Chang HM, Suwanwela NC, Huang YN, et al. Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial. Lancet Neurol 2010; 9: 489–97.
Cardoso RN, Benjo AM, DiNicolantonio JJ, Garcia DC, Macedo FY, El-Hayek G, et al. Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis. Open Heart 2015; 2: e 000248.
Choi H, Ryu J, Seo H, Kang M, Kim E . Is a high maintenance dose of clopidogrel suitable for overcoming clopidogrel resistance in patients?. Int J Clin Pharm 2015; 37: 758–61.
Chen YJ, Huang CS, Wang F, Gong JY, Pan ZH . Effect of ligustrazine hydrochloride on coagulation reaction and inflammation reaction in single valve replacement patients with rheumatic heart disease undergoing cardiopulmonary bypass. Chin J Integr Tradit West Med 2014; 34: 531–5.
Ni XJ, Liu SN, Guo XF . Medium- and long-term efficacy of ligustrazine plus conventional medication on ischemic stroke: a systematic review and meta-analysis. J Tradit Chin Med 2013; 33: 715–20.
Yan HM, Xia MF, Wang Y, Chang XX, Yao XZ, Rao SX, et al. Efficacy of berberine in patients with non-alcoholic fatty liver disease. PLoS One 2015; 10: e 0134172.
Zhang JF, Cao HL, Zhang B, Cao HW, Xu XQ, Ruan H, et al. Berberine potently attenuates intestinal polyps growth in ApcMin mice and familial adenomatous polyposis patients through inhibition of Wnt signaling. J Cell Mol Med 2013; 17: 1484–93.
Shang XB, Wu XZ, Li DH, Guo SD . Experimental study on synergistic action of Huoxue Huayu herbs on Qingjie Tongxia Herbs I. Chin J Surg Integr Tradit West Med 2006; 12: 91–4.
Shang XB, Wu XZ, Xue XP, Yang XZ, Li DH, Guo SD . Experimental studies on synergistic effect of Huoxue Huayu herbs on Qingjie Tongxia Herbs IV. Chin J Surg Integr Tradit West Med 2006; 12: 254–7.
Park SD, Baek YS, Woo SI, Kim SH, Shin SH, Kim DH, et al. Comparing the effect of clopidogrel versus ticagrelor on coronary microvascular dysfunction in acute coronary syndrome patients (TIME trial): study protocol for a randomized controlled trial. Trials 2014; 15: 151.
Willoughby SR, Luu LJ, Cameron JD, Nelson AJ, Schultz CD, Worthley SG, et al. Clopidogrel improves microvascular endothelial function in subjects with stable coronary artery disease. Heart Lung Circ 2014; 23: 534–41.
Sola S, Mir MQ, Lerakis S, Tandon N, Khan BV . Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 2006; 47: 332–7.
Dörge H, Schulz R, Belosjorow S, Post H, van de Sand A, Konietzka I, et al. Coronary microembolization: the role of TNF-α in contractile dysfunction. J Mol Cell Cardiol 2002; 34: 51–62.
Yamada T, Matsumori A, Sasayama S . Therapeutic effect of anti-tumor necrosis factor-alpha antibody on the murine model of viral myocarditis induced by encephalomyocarditis virus. Circulation 1994; 89: 846–51.
Li L, Zhao XM, Lu YG, Huang WQ, Wen WM . Altered expression of pro-and anti-inflammatory cytokines is associated with reduced cardiac function in rats following coronary microembolization. Mol Cell Biochem 2010; 342: 183–90.
Kraaijeveld AO, de Jager SCA, De Jager WJ, Prakken BJ, McColl SR, Haspels I, et al. CC chemokine ligand-5 (CCL5/RANTES) and CC chemokine ligand-18 (CCL18/PARC) are specific markers of refractory unstable angina pectoris and are transiently raised during severe ischemic symptoms. Circulation 2007; 116: 1931–41.
Cipriani S, Francisci D, Mencarelli A, Renga B, Schiaroli E, D'Amore C, et al. Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice. Circulation 2013; 127: 2114–24.
Wagner DD . New links between inflammation and thrombosis. Arterioscler Thromb Vasc Biol 2005; 25: 1321–4.
Wagner DD, Burger PC . Platelets in inflammation and thrombosis. Arterioscler Thromb Vasc Biol 2003; 23: 2131–7.
Liu GX . Meta-analysis of ligustrazine injection in the treatment of unstable angina pectoris. Modern J Integr Tradit Chin West Med 2012; 17: 4–6.
Dong H, Yan Z, Li Z, Lu FE . The effects of berberine on blood lipids: a systemic review and meta-analysis of randomized controlled trials. Planta Med 2013; 79: 437–46.
Acknowledgements
This work was supported by the National Natural Science Foundation of China (No 81030063 to Da-zhuo SHI).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Zhang, Y., Ma, Xj., Guo, Cy. et al. Pretreatment with a combination of ligustrazine and berberine improves cardiac function in rats with coronary microembolization. Acta Pharmacol Sin 37, 463–472 (2016). https://doi.org/10.1038/aps.2015.147
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/aps.2015.147
Keywords
This article is cited by
-
The role of berberine in Covid-19: potential adjunct therapy
Inflammopharmacology (2022)
